|
Baishan Jiang, PhD Professor of Medicinal Chemistry and Chemical Biology Medical Research Institute, Wuhan University Email: baishan_jiang@whu.edu.cn |
Education
2001-2005 |
B.S. |
Xiangtan University |
2005-2011 |
Ph.D. |
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences |
Work Experience
2011-2015 |
Group Leader |
Guangzhou Institutes of Biomedicine and Health |
2015-2019 |
Research Fellow |
Dana-Farber Cancer Institute, Harvard Medical School |
2019-2022 |
Research Scientist |
Dana-Farber Cancer Institute, Harvard Medical School |
2022-present |
Professor |
Medical Research Institute, Wuhan University |
Research Interest
Development of small molecule modulators, including reversible/irreversible inhibitors, bifunctional degraders and molecular glues, to target proteins of interest, and explore their applications in disease treatments.
Selected Publications
1. Li, Q. +; Jiang, B. +; Guo, J. +; Shao, H.; Del Priore, I. S.; Chang, Q.; Kudo, R.; Li, Z.; Razavi, P.; Liu, B.; Boghossian, A. S.; Rees, M. G.; Ronan, M. M.; Roth, J. A.; Donovan, K. A.; Palafox, M.; Reis-Filho, J. S.; de Stanchina, E.; Fischer, E. S.; Rosen, N.; Serra, V.; Koff, A.; Chodera, J. D.; Gray, N. S.; Chandarlapaty, S., INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors. Cancer Discovery 2021, doi: 10.1158/2159-8290.CD-20-1726 (+equal contribution).
2. Jiang, B. +; Jiang, J. +; Kaltheuner, I. H. +; Iniguez, A. B.; Anand, K.; Ferguson, F. M.; Ficarro, S. B.; Alex Seong, B. K.; Greifenberg, A. K.; Dust, S.; Kwiatkowski, N. P.; Marto, J. A.; Stegmaier, K.; Zhang, T.; Geyer, M.; Gray, N. S., Structure-Activity Relationship Study of THZ531 Derivatives Enables the Discovery of BSJ-01-175 as a Dual CDK12/13 Covalent Inhibitor with Efficacy in Ewing Sarcoma. Eur. J. Med. Chem. 2021, 221, 113481-113497 (+equal contribution).
3. Jiang, B. +; Yang, G. +; Che, J. +; Lu, W.; Kaltheuner, I. H.; Dries, R.; Kalocsay, M.; Berberich, M. J.; Jiang, J.; You, I.; Kwiatkowski, N.; Riching, K. M.; Daniels, D. L.; Sorger, P. K.; Geyer, M.; Zhang, T.; Gray, N. S., Discovery and resistance mechanism of a selective CDK12 degrader. Nat Chem Biol 2021, 17, 675-683 (+equal contribution).
4. Jiang, J. +; Jiang, B+.; Jarrod, S.; Zhang, T.H.; Gray, N.S., Characterization of a dual covalent inhibitor targeting MKK4 and MKK7. Cell Chem. Biol. 2020, 27, 1553-1560 (+equal contribution).
5. Jiang, B. +; Wang, E. S. +; Donovan, K. A.; Liang, Y.; Fischer, E. S.; Zhang, T.; Gray, N. S., Development of dual and selective degraders of cyclin-dependent kinases 4 and 6. Angew. Chem. Int. Edit., 2019, 58, 6321-6326 (equal contribution).
6. Brand, M.+; Jiang, B. +; Bauer, S.; Donovan, K. A.; Wang, E. S.; Nowak, R. P.; Yuan, J. C.; Zhang, T.; Kwiatkowski, N.; Müller, A. C.; Fischer, E. S.; Gray, N. S.; Winter, G. E., Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem. Biol., 2019, 26, 300-306 (equal contribution).
7. Browne, C. M.; Jiang, B.; Ficarro, S. B.; Doctor, Z. M.; Johnson, J. L.; Card, J. D.; Sivakumaren, S. C.; Alexander, W. M.; Yaron, T.; Murphy, C. J.; Kwiatkowski, N. P.; Zhang, T.; Cantley, L. C.; Gray, N. S.; Marto, J. A. A Chemoproteomic Strategy for Direct and Proteome-wide Covalent Inhibitor Target-site Identification. J. Am. Chem. Soc. 2019, 141, 191-203.
8. Olson, C. M.; Jiang, B.; Erb, M. A.; Liang, Y.; Doctor, Z. M.; Zhang, Z.; Zhang, T.; Kwiatkowski, N.; Boukhali, M.; Green, J. L.; Haas, W.; Fischer, E. S.; Young, R. A.; Bradner, J. E.; Winter, G. E.; Gray, N. S., Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chem. Biol., 2018, 14, 163-170.
